Have you seen an improvement in OS for patients who relapse after HSCT over the past 20 years?

During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the ALL Hub spoke to Ali Bazarbachi, American University of Beirut, Beirut, LB. We asked, Have you seen an improvement in OS for patients who relapse after HSCT over the past 20 years?

In this video, Bazarbachi discusses the long-term prognosis for adult patients with Philadelphia chromosome-positive ALL who have relapsed after allogeneic hematopoietic stem cell transplant (HSCT), with reference to the 900 patients on the EBMT registry with this ALL subtype.